Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + candonilimab + tegafur + gimeracil + oteracil potassium
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of multiple drugs: **Fruquintinib** is a highly selective oral tyrosine kinase inhibitor that targets VEGFR-1, VEGFR-2, and VEGFR-3, inhibiting angiogenesis and tumor blood vessel maturation. It has weak inhibitory effects on RET, FGFR1, and c-KIT kinases. **Candonilimab** is not described in the provided search results. **Tegafur-gimeracil-oteracil potassium (S-1)** is a combination oral fluoropyrimidine anticancer drug: - Tegafur is a prodrug of 5-fluorouracil (5-FU) with good oral absorption - Gimeracil inhibits dihydropyrimidine dehydrogenase to prevent 5-FU catabolism - Oteracil potassium inhibits phosphorylation of 5-FU, reducing gastrointestinal toxicity
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)DPYD (Dihydropyrimidine dehydrogenase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)OPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on fruquintinib + candonilimab + tegafur + gimeracil + oteracil potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + candonilimab + tegafur + gimeracil + oteracil potassium.